Piper Jaffray analyst JP McKim raised his price target for DexCom to $165 after catching up management on the company's earnings preannouncement and guidance for 2019. After the meeting the analyst is "incrementally more bullish" on shares and raises his 2019 sales estimate to $1.2B. DexCom will have success in shifting to the pharmacy and the brunt of the 10% average selling price shift to be felt in 2019 and 2020 will have minimal pricing headwinds, McKim tells investors in a research note. Further, he remains "excited" about pipeline at DexCom. The analyst keeps an Overweight rating on the shares.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here

Canaccord analyst William Plovanic raised the firm's price target on DexCom to $145 from $144 and keeps a Buy rating on the shares. The firm said they reported a slight;ly better than expected Q1 as the company raised the low-end and mid-point of its revenue guidance and reiterated its adjusted GM/OM/EBITDA margins for 2024.

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here

Pre-earnings options volume in DexCom is 11.4x normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 5.8%, or $8.05, after results are released. Median move over the past eight quarters is 5.4%.